Treatment Armamentarium for HER2+ Metastatic Breast Cancer

Video

Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.

CN-BC-ATP_Seg02
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Epithelioid Sarcoma: Histological Features and Differential Diagnoses
      Epithelioid Sarcoma: Histological Features and Differential Diagnoses
      Epithelioid Sarcoma: Overview and Presentation
      Epithelioid Sarcoma: Overview and Presentation
      4 experts in this video
      Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
      4 experts in this video
      Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
      Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
      Addressing Racial Disparities, Social Barriers to Breast Cancer Care
      4 experts in this video
      PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
      4 experts in this video
      PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
      5 experts in this video
      The Future of DLBCL: Innovations in Therapy and Patient Care
      4 experts in this video
      Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
      4 experts in this video
      Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
      Related Content
      96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

      96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

      Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
      April 18th 2025
      Article
      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

      Paolo Tarantino, MD;Matteo Lambertini, MD
      January 13th 2025
      Podcast

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

      Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

      Roman Fabbricatore
      April 17th 2025
      Article

      No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

      A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

      Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

      Rachel A. Greenup, MD, MPH
      December 23rd 2024
      Podcast

      A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

      100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

      100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

      Alexandra Vitko;Pamela K Ginex;Kelli Thoele;Qinli Lily Ma;Astra Liepa;Wambui Gathirua-Mwangi;Elyse Hall Panjic, PharmD, BCOP;Engels Chou;Jodi L Taraba;Hilary Ellis;Charlotte Clewes;Joanna de Courcy;Hope S. Rugo, MD
      April 15th 2025
      Article
      102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

      102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

      Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
      April 14th 2025
      Article